Radiation Syndrome
📧 Sign up to get email alerts when something new happens for Radiation Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-11-17EMA Authorised: Imreplys (sargramostim) — Partner Therapeutics Limited
The European Medicines Agency authorised Imreplys (sargramostim) for acute radiation syndrome, with Partner Therapeutics Limited as the mark…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: BIO 300 Oral Powder Safety and Pharmacokinetics [Phase 1]
Phase 1 clinical trial evaluating the safety and pharmacokinetics of BIO 300 oral powder in Acute Radiation Syndrome is completed, with resu…
-
EMA withdrawal · 2018-12-12EMA Application withdrawn: Entolimod TMC (Entolimod) — TMC Pharma Services Ltd
The EMA withdrew the application for Entolimod (TMC) by TMC Pharma Services Ltd for Acute Radiation Syndrome.
-
CLINICAL_TRIALS trial_result · 2016-05-05Clinical Trial Update: Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation [Phase 1]
Phase I study evaluating eltrombopag to boost platelet production after total body irradiation; the trial has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-10-27Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers [Phase 1]
A Phase 1 clinical trial update evaluating the safety and pharmacokinetics of RadProtect in healthy volunteers for Acute Radiation Syndrome.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-17Clinical Trial Update: Safety and Pharmacokinetic Study of BIO 300 Capsules [Phase 1]
Phase 1 safety and pharmacokinetic study of BIO 300 capsules completed, reporting safety and pharmacokinetic data in Acute Radiation Syndrom…